Immunity, Infection, and Defense System Function

Primary Divisions of the Immune System

• Innate Immune System:

  • Represents the first line of non-specific general defense with which an individual is born.
  • Provides immediate protection through anatomical barriers, cellular responses, and pre-existing humoral systems.
  • Operates non-specifically against a wide variety of foreign pathogens without requiring prior exposure.

• Adaptive Immune System:

  • Serves as the secondary, highly specific defense system activated upon exposure to specific microbes, foreign proteins, or chemical antigens.
  • Involves antigen recognition, clonal expansion, and the development of immunological memory.
  • Generates enhanced, rapid responses upon subsequent exposures to the same specific antigen.

Classification and Types of Immunity

• Active Immunity:

  • Occurs when the individual's immune system actively produces its own antibodies and memory cells in response to antigen exposure.
  • Natural Active Immunity: Acquired through direct natural exposure to an infectious pathogen (e.g., contracting and recovering from wild-type infection such as measles or varicella).
  • Artificial Active Immunity: Induced through controlled administration of attenuated, inactivated, or recombinant antigens via vaccination (e.g., receiving an MMR or influenza vaccine).

• Passive Immunity:

  • Conferred by the direct transfer of preformed antibodies into an individual, offering immediate but temporary protection without stimulating host memory cell production.
  • Natural Passive Immunity: Maternal transfer of preformed antibodies to the fetus across the placenta ($\text{IgG}$) or to the infant through colostrum and breast milk ($\text{IgA}$).
  • Artificial Passive Immunity: Administration of exogenous antibodies or immunoglobulins harvested from immune human or animal donors (e.g., antivenoms, antitoxins, or intravenous immunoglobulin $\text{IVIG}$ infusions).

Cellular Components of the Defense System

• Leukocytes (White Blood Cells):      

  • Categorized structurally based on cytoplasmic granules into Granulocytes and Agranulocytes.
  • Granulocytes:
  • Neutrophils: Phagocytic granulocytes featuring multi-lobed nuclei. Act as the primary first responders recruited to sites of acute tissue infection or acute inflammation, engulfing and destroying bacteria and fungi.
  • Eosinophils: Specialized granulocytes active in defense against multicellular parasitic infections and major contributors to allergic responses and asthmatic airway inflammation.
  • Basophils: Circulating granulocytes containing dense histamine and heparin granules that mediate immediate hypersensitivity and systemic allergic responses.
  • Agranulocytes:
  • Monocytes: Large mononuclear leukocytes circulating in blood that extravasate into tissue spaces to differentiate into tissue macrophages and dendritic cells.
  • Lymphocytes: Core agranulocytes orchestrating adaptive and innate cellular immunity; include B-cells, T-cells, and Natural Killer cells.

• Lymphocytes and Antigen Presentation:      

  • B-Cells: Mediate humoral immunity; upon activation, differentiate into plasma cells capable of secreting antigen-specific antibodies (immunoglobulins).
  • T-Cells: Mediate cell-mediated immunity; utilize T-cell receptors ($\text{TCRs}$) to bind processed peptide antigens presented on Major Histocompatibility Complex ($\text{MHC}$) molecules, secreting regulatory cytokines or executing direct target lysis.
  • Monocytes and Macrophages: Function as professional antigen-presenting cells ($\text{APCs}$), processing phagocytosed pathogens and displaying peptide fragments on surface $\text{MHC}$ complexes to naive lymphocytes.

• Dendritic Cells:      

  • Specialized professional antigen-presenting cells featuring extensive, branching cytoplasmic projections.
  • Reside in peripheral barrier tissues, capture antigens, and migrate to secondary lymphoid organs to present processed antigens to naive T-cells, serving as a critical bridge between innate and adaptive immunity.

• Natural Killer (NK) Cells:      

  • Innate cytotoxic lymphocytes capable of identifying and killing virally infected host cells and malignant tumor cells without prior antigen sensitization.
  • MHC Class I Regulation:
  • Typical healthy nucleated host cells express surface MHC Class I molecules.
  • NK cells feature Killer-Inhibitory Receptors (KIR) that recognize $\text{MHC Class I}$. Binding of $\text{MHC Class I}$ delivers inhibitory signals that suppress cell killing ("No attack").
  • NK cells also express Killer-Activating Receptors (KAR) that recognize ubiquitous surface molecules on stress-exposed cells.
  • Atypical cells (such as virally infected cells or transformed tumor cells) downregulate or lose $\text{MHC Class I}$ expression ("missing self"). Loss of $\text{MHC Class I}$ leaves $\text{KAR}$ engagement unopposed, triggering NK cell degranulation of perforin (membrane pore formation) and granzymes (induction of target apoptosis) to kill the cell ("Kill").

Organs and Tissues of the Lymphoid System

• Primary Lymphoid Organs:

  • Bone Marrow:          
  • Structure: Composed of outer compact bone enclosing trabecular spongy bone, containing central vascularized yellow marrow and hematopoietically active red bone marrow.
  • Hematopoiesis: Houses multipotent blood stem cells that continuously generate all blood lineages, including red blood cells, platelets, granulocytes, monocytes, B-lymphocytes, and immature T-cell precursors.
  • Site of complete B-cell origin, maturation, and central tolerance selection.
  • Thymus:
  • Bi-lobed lymphoid organ situated in the anterior superior mediastinum.
  • Site of T-cell precursor maturation, T-cell receptor gene rearrangement, and thymic selection (elimination of self-reactive T-cells).

• Secondary Lymphoid Organs and Tissues:

  • Spleen: Abdominal lymphoid organ that filters systemic circulation, removes senescent erythrocytes, and initiates adaptive immune responses against blood-borne pathogens.
  • Lymph Nodes: Encapsulated structures distributed along lymphatic channels that filter lymph, entrap interstitial antigens, and house organized regions of B-cells and T-cells to facilitate antigen presentation.
  • Mucosa-Associated Lymphoid Tissue (MALT):
  • Unencapsulated lymphoid aggregations located within vulnerable mucosal linings directly exposed to external environments.
  • Key anatomical sites include:
    • Mucous membranes of the nose, throat, and pharynx (including tonsils).
    • Gastrointestinal tract mucosal linings (bowel lymphoid aggregations / Peyer's patches).
    • Mucous membranes in the urinary bladder and genital tract.
    • Cutaneous immune networks in the skin.

Physical Barriers, Chemical Defenses, and Complement

• Barrier Defenses:

  • Skin: Intact keratinized stratified squamous epithelium functioning as a primary physical barrier; cutaneous glands secrete acidic sebum and sweat to inhibit microbial surface colonization.
  • Mucous Membranes: Epithelial tissue lining respiratory, digestive, and urogenital tracts; secretes viscid mucus to physically trap microorganisms. The respiratory tract utilizes ciliated epithelium (mucociliary escalator) for continuous mechanical clearance.
  • Chemical Barriers: Gastric acid in the stomach provides an extreme low-pH environment destroying ingested pathogens; tears, saliva, and nasal secretions contain antimicrobial lysozyme and secretory $\text{IgA}$.

• The Complement System:

  • Cascade of plasma proteins synthesized by the liver that circulate in inactive precursor forms.
  • Activated via classical (antibody-bound), lectin (carbohydrate-binding), or alternative (spontaneous surface cleavage) pathways.
  • Executes host defense by promoting opsonization (tagging targets for phagocytosis), releasing anaphylatoxins ($\text{C3a}$, $\text{C5a}$) to drive leukocyte chemotaxis and vasodilation, and constructing the Membrane Attack Complex ($\text{MAC}$, $\text{C5b-C9}$) to induce target cell lysis.

Dynamic Interplay Between Innate and Adaptive Immunity

• Innate and Adaptive Spectrum:

  • Innate Immune Components: Natural killer cells, Neutrophils, Eosinophils, Basophils, Mast cells, Macrophages, Complement proteins, and Dendritic cells.
  • Bridge Cells: Natural Killer T-cells and Dendritic cells.
  • Adaptive Immune Components: B-cells (and secreted Antibodies), T-cells (divided into $\text{CD4+}$ Helper T-cells and $\text{CD8+}$ Cytotoxic T-cells).

• Sequential Immune Response Timeline:

  1. Immediate Innate Response: Upon mucosal or cutaneous breach, local pathogen invasion occurs. Resident innate immune cells (macrophages, neutrophils) immediately recognize pathogens and initiate rapid phagocytosis at the injury site.
  2. Signaling & Chemotaxis: Engulfment and cellular activation trigger local release of soluble signaling molecules (chemokines and cytokines).
  3. Antigen Processing & Migration: Antigen-presenting cells (dendritic cells) internalize pathogen debris, drain into lymphatic vessels, and travel to local lymph nodes.
  4. Delayed Adaptive Response: In lymph nodes, $\text{APCs}$ present processed peptide antigens to naive T-cells and B-cells, driving antigen-specific clonal expansion.
  5. Effector Execution: Differentiated B-cells secrete targeted immunoglobulins; $\text{CD8+}$ cytotoxic T-cells migrate to tissue infection sites to eliminate infected host cells displaying matching antigens; $\text{CD4+}$ T-cells coordinate inflammatory activity.

Cell-Mediated vs. Humoral Immunity

• Cell-Mediated Immunity:

  • Mediated primarily by T-lymphocytes.
  • Targets intracellular pathogens (viruses, intracellular bacteria, fungal organisms) and mutated or transplanted host cells.
  • $\text{CD4+}$ Helper T-Cells: Recognize peptide antigens bound to $\text{MHC Class II}$ molecules; release cytokines to activate macrophages, $\text{CD8+}$ T-cells, and B-cells.
  • $\text{CD8+}$ Cytotoxic T-Cells: Recognize endogenous antigens presented on $\text{MHC Class I}$ molecules; directly induce cell lysis and apoptosis in compromised target host cells.

• Humoral Immunity:

  • Mediated primarily by B-lymphocytes and circulating Antibodies (Immunoglobulins).
  • Targets extracellular pathogens (extracellular bacteria, circulating viruses, soluble toxins) in body fluids (blood, lymph, interstitial fluid).
  • Upon antigen binding to B-cell receptors ($\text{BCR}$), B-cells undergo clonal selection and differentiate into antibody-secreting plasma cells. Secreted immunoglobulins neutralize, opsonize, and agglutinate targets while activating classical complement pathways.

The Chain of Infection and Transmission Control

• Elements of the Chain of Infection:

  • Infectious Agent: Pathogenic microorganism (bacteria, virus, fungus, parasite).
  • Reservoir: Natural environment, organism, or object where pathogen survives and multiplies (e.g., central blood vessels, indwelling urinary catheter, soil, human host).
  • Portal of Exit: Anatomical route by which pathogen leaves reservoir (e.g., respiratory tract, gastrointestinal tract, genitourinary tract, non-intact skin, surgical wounds, blood).
  • Mode of Transmission: Specific mechanism by which pathogen moves from reservoir to host.
  • Portal of Entry: Anatomical site where pathogen enters susceptible host (e.g., nose/nasal mucosa, oral cavity, non-intact skin/cuts/surgical wounds, urethra/bladder/urinary catheters, central vascular access devices).
  • Susceptible Host: Individual with reduced immune resistance or compromised defense barriers.

• Breaking the Chain of Infection:

  • Infection control strategies target specific links to halt transmission (e.g., hand hygiene and barrier precautions interrupt transmission modes; immunizations lower host susceptibility; sterilization eliminates reservoirs).

Modes of Disease Transmission

• Contact Transmission:

  • Direct Contact: Person-to-person physical transfer of pathogens through skin-to-skin touch, kissing, or sexual contact.
  • Indirect Contact: Transfer of pathogens via intermediate contaminated inanimate objects (fomites), such as medical equipment, door handles, dressings, or dirty linens.

• Droplet Transmission:

  • Dissemination of large infectious respiratory droplets ($> 5-10\,\mu\text{m}$) generated during coughing, sneezing, or speaking; droplets travel short distances (typically $\le 3-6\,\text{feet}$) before settling.

• Airborne Transmission:

  • Dissemination of evaporated droplet nuclei or microscopic dust particles ($\le 5\,\mu\text{m}$) containing infectious agents that remain suspended in air currents over extended time periods and long distances.

• Vehicle and Vector-Borne Transmission:

  • Vehicle Transmission: Transmission via contaminated passive media including water, food, drugs, or transfused blood products.
  • Vector-Borne Transmission: Transmission mediated by living arthropod vectors (e.g., mosquitoes, ticks, fleas, mites) that carry pathogens between hosts.

Infection Stages and Classification

• Stages of Infection:

  • Incubation Period: Time interval between initial pathogen entry and the first appearance of clinical signs or symptoms; pathogen actively multiplies.
  • Prodromal Stage: Early phase characterized by non-specific, generalized symptoms (malaise, low-grade fever, fatigue); highly infectious period.
  • Acute Illness Stage: Phase of peak clinical severity where characteristic, localized, and systemic diagnostic signs and symptoms manifest.
  • Decline Stage: Decreasing pathogen burden due to host immune defense and medical intervention; clinical symptoms resolve.
  • Convalescence Period: Tissue repair and complete recovery phase; return to baseline health status.

• Local vs. Systemic Infections:

  • Local Infections: Infection confined strictly to a single localized anatomical site or tissue (e.g., localized abscess, cellulitis).
  • Systemic Infections: Microorganisms or their toxins disseminate throughout the entire organism via blood or lymph (e.g., bacteremia, septicemia).

Bacterial Infections

• Pathogenesis and Timeline:      

  1. Bacterial Exposure: Initial contact between bacterial pathogen and host surface.
  2. Colonization: Bacterial adhesion and surface proliferation without immediate tissue destruction (comprises Asymptomatic Phase).
  3. Immune Evasion: Pathogens employ capsules, biofilms, or enzymatic destruction to bypass host phagocytes and complement.
  4. Infection: Tissue invasion and toxic injury trigger host inflammatory pathways (comprises Symptomatic Phase).

• Diagnostic Criteria and Antibiotic Sensitivity:      

  • Culture and Sensitivity (C&S) Testing:
  1. Clinical specimen from suspected infection site is inoculated onto agar media.
  2. Antibiotic-impregnated paper disks (labeled A, B, C, D) are placed onto the inoculated surface.
  3. Following incubation, clear circular Zones of Inhibition around disks demonstrate bacterial sensitivity to the specific antimicrobial agent (e.g., Disk A shows large inhibition zone = high susceptibility; Disk C shows no zone = resistance).

• Management:

  • Targeted antimicrobial drug therapy selecting agents with appropriate minimum inhibitory concentrations, combined with source control measures.

Viral Infections

• Pathogenesis and Clinical Dissemination:      

  • Obligate intracellular pathogens requiring host cellular metabolic machinery for genomic replication and viral protein synthesis.
  • Inhalation or mucosal contact with viral particles leads to cellular attachment, internal entry, genomic replication, viral particle assembly, and host cell destruction, generating tissue inflammation and systemic viral signs.

• Diagnostic Criteria and Management:      

  • Diagnostics: Nasopharyngeal swab collection evaluated via Polymerase Chain Reaction ($\text{PCR}$), antigen assays, or viral isolation.
  • Management:
  • Supportive Care: Hydration, rest, antipyretic administration, oxygen therapy.
  • Antivirals: Specific viral enzymes inhibitors (e.g., reverse transcriptase or neuraminidase inhibitors).
  • Vaccination: Prophylactic immunization to induce humoral and cellular immune memory.

Fungal Infections

• Etiology and Pathogenesis:

  • Eukaryotic yeasts or molds causing opportunistic or primary fungal diseases.
  • Clinical manifestations range across three structural levels:
  • Cutaneous or Mucosal Infections: Superficial epidermal or mucosal tissue involvement.              
    • Example: Oral Candidiasis (thrush), presenting as confluent white pseudomembranous coatings on the tongue and oral mucosa.              
    • Example: Tinea corporis (ringworm), manifesting as an erythematous, scaly, annular ring lesion with raised scaling borders and central clearing.
  • Subcutaneous Tissue and Organ Infections: Deep dermal or localized organ fungal involvement.
  • Systemic Infections: Disseminated invasive fungal disease involving deep visceral organs and blood stream, typically in immunocompromised hosts.

• Diagnostics and Management:

  • Diagnostic criteria include KOH direct microscopy, fungal culture, histopathological staining, and serum fungal antigen assays.
  • Management relies on preventative hygiene protocols and targeted antifungal medications (azoles, polyenes, echinocandins).

Parasitic Infections

• Classes and Manifestations:

  • Parasitic organisms include protozoa, helminths, and ectoparasites.      
  • Helminthic Infections: Multi-cellular parasitic worms (nematodes, trematodes, cestodes) infecting intestinal or extra-intestinal tissues.      
  • Skin Infestations: Ectoparasitic infestation by microscopic arthropods such as Sarcoptes scabiei (scabies mite). Female mites burrow into the stratum corneum of human skin, carving intraepidermal tunnels to lay eggs, producing intense allergic pruritus and papular cutaneous eruptions.

• Diagnostics and Management:

  • Diagnostic criteria: Microscopic evaluation of stool for Ova and Parasites (\text{O&P}), skin scrapings, serological assays.
  • Management: Antiparasitic/antihelminthic medications (e.g., permethrin, ivermectin) and supportive clinical care.

Pathogen Recognition and Acute Inflammation Activation

• Pathogen Recognition:

  • Pattern Recognition Receptors ($\text{PRRs}$) on host immune cells recognize Pathogen-Associated Molecular Patterns ($\text{PAMPs}$) on microbes or Damage-Associated Molecular Patterns ($\text{DAMPs}$) from injured host cells.

• Stepwise Inflammatory Cascade:      

  1. Pattern Recognition: Cell-surface pattern receptors bind directly to harmful stimuli.
  2. Pathway Activation: Binding triggers intracellular signaling cascades.
  3. Marker Release: Synthesis and immediate release of soluble inflammatory markers (histamine, prostaglandins, bradykinin, cytokines).
  4. Cell Recruitment: Mediators induce vasodilation and vascular permeability, recruiting inflammatory leukocytes to the affected site.

Acute Inflammation: Pathophysiology and PRISH Signs

• Etiology:

  • Exogenous Triggers: Physical injury, mechanical trauma, thermal burns, chemical toxins, microbial infection.
  • Endogenous Triggers: Tissue ischemia, infarction, immune complex deposition, autoantibody reactions.

• Microvascular Changes and Phagocyte Migration:      

  1. Tissue Barrier Breach: Mechanical insult introduces bacteria into subepithelial tissues; damaged tissue cells release chemical signals.
  2. Vascular Permeability & Clotting: Local capillaries dilate and expand endothelial gaps. Fluid, protein exudate, and platelets enter the tissue to initiate localized clotting.
  3. Leukocyte Extravasation: Neutrophils and monocytes undergo diapedesis across capillary walls, migrate toward chemotactic signals, and perform phagocytosis to destroy bacteria and cellular debris.

• Five Cardinal Manifestations (PRISH Acronym):      

  • P - Pain (Dolor): Nerve terminal stimulation resulting from tissue swelling tension and chemical mediators (bradykinin, prostaglandins).
  • R - Redness (Rubor): Erythema driven by localized arteriolar vasodilation and increased microvascular blood flow.
  • I - Immobility / Loss of Function (Functio Laesa): Temporary loss of affected tissue movement or function due to pain and swelling.
  • S - Swelling (Tumor): Accumulation of fluid and protein exudate within interstitial spaces.
  • H - Heat (Calor): Localized hyperthermia secondary to enhanced blood flow and metabolic activity.

• Management of Acute Inflammation:      

  • Mild Localized Inflammation: Managed conservatively using the PRICE protocol:
  • P - Protect: Guard injured region against additional injury (braces, splints).
  • R - Rest: Avoid movement or weight-bearing to limit tissue strain.
  • I - Ice: Apply cryotherapy to promote vasoconstriction, reducing swelling and pain.
  • C - Compression: Utilize elastic compression wraps to minimize interstitial fluid accumulation.
  • E - Elevate: Position injured limb above heart level to facilitate fluid drainage.
  • Moderate Inflammation: Pharmacological management using $\text{NSAIDs}$ or corticosteroids to inhibit cyclooxygenase enzymes and cytokine production.
  • Severe Systemic Inflammation: Systemic Inflammatory Response Syndrome ($\text{SIRS}$) requires intensive care monitoring and aggressive fluid/hemodynamic resuscitation.

Chronic Inflammation and Pathological Implications

• Etiology and Pathogenesis:

  • Pathological inflammatory state lasting weeks, months, or years caused by persistent infections, ongoing toxic exposures, or autoimmune diseases.
  • Tissue destruction, active inflammatory infiltrate (macrophages, lymphocytes, plasma cells), and inadequate repair efforts occur simultaneously.

• Systemic Clinical Manifestations:      

  • Systemic manifestations span multiple body systems:
  • Neurological/Psychological: Mood alterations, lethargy, sleep disruption.
  • General: Fever, increased susceptibility to frequent infections.
  • Musculoskeletal: Joint pain or stiffness.
  • Gastrointestinal: Oral ulcers, acid reflux, abdominal pain, diarrhea or constipation.
  • Cardiopulmonary: Chest pain.
  • Integumentary: Skin rashes.
  • Metabolic: Unexplained weight gain or weight loss.

• Tissue Fibrosis:      

  • Persistent macrophage signaling and fibrogenic cytokines stimulate fibroblast proliferation, transforming normal cellular parenchyma into non-functional fibrotic collagenous scar tissue.

• Adipokine Signaling in Obesity:      

  • Obese State: Hypertrophic adipose tissue secretes elevated Proinflammatory Adipokines, driving systemic inflammatory tone and predisposing to:
  • Insulin resistance
  • Cardiovascular diseases
  • Metabolic syndrome
  • Non-Obese State: Normal adipose tissue secretes Anti-Inflammatory Adipokines (such as adiponectin), promoting:
  • Insulin sensitivity
  • Cardioprotective effects
  • Efficient tissue glucose uptake

Immune Tolerance, Autoimmunity, and Hypersensitivity

• Immune Tolerance:

  • State of specific immunological unresponsiveness to autologous self-antigens.
  • Central Tolerance: Takes place during early lymphocyte maturation in primary lymphoid organs (bone marrow, thymus); self-reactive clones undergo deletion or receptor editing.
  • Peripheral Tolerance: Operates in peripheral tissues via clonal anergy, T-regulatory cell suppression, or activation-induced apoptosis to control mature self-reactive cells escaping central selection.

• Autoimmunity:

  • Breakdown of self-tolerance resulting in immune-mediated attack against host tissues.
  • Organ-Specific Autoimmune Disease: Directs damage against a single organ (e.g., Type 1 Diabetes Mellitus targeting pancreatic beta cells).
  • Systemic Autoimmune Disease: Directs damage against ubiquitous autoantigens across multiple organs (e.g., Systemic Lupus Erythematosus).

• Hypersensitivity Classifications (Types I–IV):

  • Type I (Immediate / Anaphylactic): $\text{IgE}$-mediated; antigen cross-links $\text{IgE}$ on mast cells/basophils, causing rapid release of histamine and vasoactive amines (e.g., anaphylaxis, allergic asthma).
  • Type II (Cytotoxic / Antibody-Mediated): $\text{IgG}$ or $\text{IgM}$ antibodies bind cell-surface antigens, activating complement lysis or $\text{ADCC}$ (e.g., blood transfusion reactions).
  • Type III (Immune Complex-Mediated): Circulating soluble antigen-antibody complexes deposit in vessel walls, activating complement and attracting neutrophils (e.g., serum sickness, lupus nephritis).
  • Type IV (Delayed-Type / Cell-Mediated): T-cell mediated; sensitized T-lymphocytes release cytokines or induce direct cellular cytotoxicity $\text{24-72 hours}$ post-exposure (e.g., contact dermatitis, tuberculin skin test).

Immunodeficiency Disorders

• Primary Immunodeficiencies:

  • Congenital or genetic defects present from birth that impair baseline immune cell development or function (e.g., Severe Combined Immunodeficiency $\text{SCID}$, X-linked agammaglobulinemia).

• Secondary Immunodeficiencies:

  • Acquired immune deficits resulting from external factors such as malnutrition, immunosuppressive drug therapy, malignancy, or chronic infections.
  • Human Immunodeficiency Virus (HIV): Prototypical secondary immunodeficiency retrovirus that targets and progressively depletes $\text{CD4+}$ T-helper cells, leading to Acquired Immunodeficiency Syndrome ($\text{AIDS}$).

Transplantation Biology and Rejection Dynamics

• Transplant Rejection Mechanisms:

  • Immune-mediated destruction of donor allografts caused by recipient recognition of foreign donor $\text{MHC/HLA}$ antigens.

• Rejection Classifications:

  • Hyperacute Rejection: Occurs within minutes to hours post-transplant; caused by pre-existing donor-specific antibodies binding graft vascular endothelium, leading to immediate thrombosis and graft necrosis.
  • Acute Rejection: Occurs within days to months; mediated by cellular T-cell responses and de novo antibody production targeting graft parenchyma.
  • Chronic Rejection: Occurs slowly over months to years; characterized by low-grade immune injury driving progressive vascular intimal thickening, smooth muscle proliferation, and interstitial fibrosis.

Immunological Aspects of Cancer Progression

• Steps in Cancer Progression:      

  1. Initiation: Irreversible genetic DNA mutation induced in a single somatic cell by carcinogen exposure.
  2. Promotion: Selective proliferation and monoclonal expansion of initiated cells driven by growth factors or chronic inflammation.
  3. Progression: Acquisition of additional mutations conferring invasive growth, intravasation into blood/lymphatic vessels, immune surveillance evasion, extravasation, and distant metastasis.

• Histological Classifications of Cancer:      

  • Carcinomas: Malignancies arising from Epithelial cells (skin, linings of body cavities, and internal organs).
  • Leukemias: Malignancies of Blood cells and hematopoietic precursors originating in bone marrow.
  • Sarcomas: Malignancies originating in connective or mesenchymal tissues (Bones and soft tissues).
  • Myelomas: Malignancies of Plasma cells (the mature B-cells responsible for antibody production).
  • Lymphomas: Malignancies originating in lymphoid organs of the Immune system (lymph nodes, spleen, stomach, testicles).
  • Mixed Types: Tumors deriving from multiple embryonic germ layers or cell types.

External Factors Influencing Immunity

• Nutrition: Balanced macro- and micronutrient supply is vital for maintaining cellular proliferation, protein synthesis, and immunoglobulin production.
• Lifestyle Factors:
  • Smoking Cessation: Preserves respiratory ciliary function and epithelial barrier defenses.
  • Sleep Hygiene: Restorative sleep supports balanced cytokine secretion and T-cell function.
  • Regular Physical Exercise: Enhances systemic leukocyte circulation and anti-inflammatory tone.
• Vaccines: Provides targeted proactive exposure to stimulate active adaptive memory without causing clinical disease.

Hand Hygiene Protocols and Asepsis

• 12-Step Hand Hygiene Technique:      

  1. Wet hands thoroughly with clean running water.
  2. Apply adequate soap to cover all hand surfaces.
  3. Rub palms directly together.
  4. Place right palm over left dorsum with interlaced fingers, and vice versa.
  5. Rub palms together with fingers interlaced.
  6. Interlock finger backs into opposing palms.
  7. Perform rotational rubbing of left thumb clasped in right palm, and vice versa.
  8. Perform rotational rubbing of clasped fingers forward and backward in palms.
  9. Rinse hands thoroughly with water.
  10. Dry hands completely using a single-use paper towel.
  11. Turn off water faucet using the paper towel.
  12. Hands are safe.

• Aseptic Terminology and Practices:

  • Antimicrobial Soap: Soap containing active chemical agents to kill or inhibit microbial flora.
  • Alcohol-Based Hand Sanitizer: Preferred product for routine hand decontamination when hands are not visibly soiled.
  • Medical Asepsis ("Clean Technique"): Practices designed to reduce pathogen numbers and block transmission (e.g., hand hygiene, routine environmental cleaning, clean gloving).
  • Surgical Asepsis ("Sterile Technique"): Meticulous practices designed to eliminate ALL microorganisms and spores from an object or field (e.g., surgical gloving, sterile field maintenance, sterile draping).
  • Sterilization: Total destruction of all microbial life including bacterial endospores (e.g., autoclaving, ethylene oxide).
  • Disinfection: Destruction of vegetative pathogens on inanimate surfaces, excluding high-resistance endospores.

Infection Control Isolation Precautions

• Standard Precautions: Basic safety practices applied to all patients in any health care setting, regardless of suspected infection status.

• Contact Precautions: Implemented for pathogens spread via direct or indirect touch (e.g., C. difficile, $\text{VRE}$, $\text{MRSA}$); requires gown and gloves upon entry and dedicated equipment.

• Droplet Precautions: Implemented for pathogens spread via large respiratory droplets (e.g., influenza); requires surgical mask placement.

• Airborne Precautions: Implemented for pathogens suspended in air over long distances (e.g., tuberculosis, varicella, measles); requires $\text{N95}$ respirator or $\text{PAPR}$ and negative pressure isolation.

• Airborne Infection Isolation Room (AIIR):      

  • Features negative air pressure differential relative to adjacent corridors, causing air to flow into the room rather than out into clean areas.
  • Exhaust air is drawn through high-efficiency particulate air ($\text{HEPA}$) filters and discharged directly outside or recirculated through specialized fan systems.
  • The isolation room functions as the contaminated area while the corridor remains protected.

• Special Isolation Scenarios:

  • COVID-19 Precautions: Combines airborne/droplet precautions with full facial protection (face shields) and contact barrier precautions.
  • Protective Isolation (Neutropenic Isolation): Features positive air pressure airflow and $\text{HEPA}$ filtration to protect severely immunocompromised hosts from environmental fungal spores and external pathogens.

Health Care-Associated Infections and Safety

• Health Care-Associated Infections (HAIs):

  • Central Line-Associated Bloodstream Infections (CLABSIs): Vascular bloodstream infections associated with central venous catheters.
  • Catheter-Associated Urinary Tract Infections (CAUTIs): Urinary tract infections linked to indwelling urinary catheters.
  • Surgical Site Infections (SSIs): Infections occurring at surgical incision sites or deep tissue planes.
  • Ventilator-Assisted Pneumonias (VAPs): Lower respiratory tract infections linked to mechanical ventilation tubes.
  • Infection Control Bundles: Standardized groups of evidence-based interventions executed together to eliminate $\text{HAI}$ risks.

• Multidrug-Resistant Organisms (MDROs):

  • Pathogens resistant to multiple antimicrobial classes (e.g., $\text{MRSA}$, $\text{VRE}$).
  • Requires strict handwashing, glove use, contact precautions, and Enhanced Barrier Precautions in long-term care settings.

• Factors Increasing Risk of Infection:

  • Exposure to health care environments.
  • Presence of indwelling medical devices (intravenous lines, central catheters, urinary catheters, tubes, drains).
  • Open skin wounds, surgical incisions, or trauma breaches.

• Personal Protective Equipment (PPE) Protocols:

  • Donning Sequence: Gown $\rightarrow$ Mask/Respirator $\rightarrow$ Goggles/Face Shield $\rightarrow$ Gloves.
  • Doffing Sequence: Gloves $\rightarrow$ Goggles/Face Shield $\rightarrow$ Gown $\rightarrow$ Mask/Respirator (followed immediately by hand hygiene).

• Needlestick Injury Prevention:

  • Designed to prevent transmission of bloodborne pathogens ($\text{HBV}$, $\text{HCV}$, $\text{HIV}$).
  • Requires use of safety-engineered sharps devices, immediate safety mechanism activation, complete prohibition of manual needle recapping, and disposal into rigid biohazard sharps containers.

• Linens and Medical Waste Management:

  • All used linen and medical waste are assumed to be contaminated.
  • Linen must be bagged without agitating to prevent airborne microbial dispersion; infectious waste is disposed of in designated biohazard containers.